Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post...
-
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital...
-
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021...
-
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
-
- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE)...
-
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
-
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
-
- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultragenyx...
-
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
-
-Additional expertise expected to support attainment of key corporate goals- CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company...